Citations 1497

P4‐254: Predicting brain amyloidosis in MCI using clinical, cognitive, imaging and peripheral blood protein measures

Alzheimer's & Dementia | March 29, 2014 | Volume: 8 | Issue: 4S_Part_20 | Pages: No page available

10.1016/j.jalz.2013.08.036

Estimating long‐term multivariate progression from short‐term data

Alzheimer's & Dementia | March 22, 2014 | Volume: 10 | Issue: 5S | Pages: No page available

10.1016/j.jalz.2013.10.003 | PMID 24656849

AbstractMotivationDiseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich panel of novel cognitive tests, biomarkers, and brain images collected every 6 months for as long as 6 years. The relative timing of the observations with respect to disease pathology is unknown. We propose a general semiparametric model and iterative estimation procedure to estimate simultaneously the pathological timing and long‐term growth curves. The resulting estimates of long‐term progression are fine‐tuned using cognitive trajectories derived from the long‐term “Personnes Agées Quid” study.ResultsWe demonstrate with simulations that the method can recover long‐term disease trends from short‐term observations. The method also estimates temporal ordering of individuals with respect to disease pathology, providing subject‐specific prognostic estimates of the time until onset of symptoms. When the method is applied to ADNI data, the estimated growth curves are in general agreement with prevailing theories of the Alzheimer's disease cascade. Other data sets with common outcome measures can be combined using the proposed algorithm.AvailabilitySoftware to fit the model and reproduce results with the statistical software R is available as the grace package. ADNI data can be downloaded from the Laboratory of NeuroImaging.
Association of type 2 diabetes with brain atrophy and cognitive impairment

Neurology | March 20, 2014 | Volume: 82 | Issue: 13 | Pages: 1132-1141

10.1212/wnl.0000000000000269 | PMID 24647028

Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study

Neurology | December 27, 2013 | Volume: 82 | Issue: 1 | Pages: 70-76

10.1212/01.wnl.0000438229.56094.54 | PMID 24371306

Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia

European Journal of Neurology | December 16, 2013 | Volume: 21 | Issue: 7 | Pages: 1040-1043

10.1111/ene.12331 | PMID 24330306

Background and purposeA subset of patients with Alzheimer's disease (AD) present with early and prominent language deficits. It is unclear whether the burden of underlying β‐amyloid pathology is associated with language or general cognitive impairment in these subjects.MethodsThe relationship between cortical β‐amyloid burden on [11C]Pittsburgh compound B (PiB) positron emission tomography (PET) and performance on the Montreal Cognitive Assessment (MoCA), the Wechsler Memory Scale − Third Edition (WMS‐III), the Boston Naming Test (BNT) and the Western Aphasia Battery (WAB) was assessed using regression and correlation analyses in subjects presenting with aphasia who showed β‐amyloid deposition on PiB PET.ResultsThe global PiB ratio was inversely correlated with MoCA (P = 0.02) and the WMS‐III Visual Reproduction (VR) subtest (VR I, P = 0.02; VR II, P = 0.04). However, the correlations between PiB ratio, BNT (P = 0.13), WAB aphasia quotient (P = 0.11) and WAB repetition scores (P = 0.34) were not significant.ConclusionThis study demonstrates that an increased cortical β‐amyloid burden is associated with cognitive impairment, but not language deficits, in AD subjects presenting with aphasia. The results suggest that β‐amyloid deposition could be partly contributing to impaired cognition in such patients whilst language dysfunction may be more influenced by other pathological mechanisms, perhaps downstream pathways of β‐amyloid deposition.
Establishing Magnetic Resonance Images Orientation for the EADC‐ADNI Manual Hippocampal Segmentation Protocol

Journal of Neuroimaging | November 27, 2013 | Volume: 24 | Issue: 5 | Pages: 509-514

10.1111/jon.12065 | PMID 24279479

ABSTRACTBACKGROUND AND PURPOSEAn effort to define and validate a Harmonized Protocol for standard hippocampal segmentation is being carried out. We wished to estimate the effect of magnetic resonance image (MRI) spatial orientation on manual hippocampal segmentations to define optimal standard orientation of MRIs for hippocampal volumetry.METHODSThree expert tracers segmented twice the hippocampi of 10 ADNI subjects on MRI slices oriented perpendicular to the anterior‐posterior commissure (AC‐PC) line and the long hippocampal axes plane, following internationally harmonized landmarks. We computed intra and interrater reliability figures for total volumes and similarity coefficients.RESULTSTotal volume reliability was similar for both orientations. Similarity coefficients were significantly higher for the AC‐PC orientation (exact P = 0.002).DISCUSSIONThese data show that AC‐PC orientation is slightly more reliable for manual segmentations, possibly due to better visualization of the cerebrospinal fluid spaces separating hippocampal head and amygdala. A Delphi panel of experts has used these data to decide on the optimal orientation for a Harmonized Protocol for hippocampal segmentation.
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease

Proceedings of the National Academy of Sciences | November 5, 2013 | Volume: 110 | Issue: 47 | Pages: No page available

10.1073/pnas.1317918110 | PMID 24194552

Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity

Neurology | October 18, 2013 | Volume: 81 | Issue: 20 | Pages: 1732-1740

10.1212/01.wnl.0000435556.21319.e4 | PMID 24132377

MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies

Neurology | October 11, 2013 | Volume: 81 | Issue: 19 | Pages: 1681-1689

10.1212/01.wnl.0000435299.57153.f0 | PMID 24107861

IC‐P‐089: FDG‐PET and PiB‐PET imaging in asymptomatic at‐risk carriers of a novel octapeptide repeat insertion in PRNP

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2013.05.086